Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,748.75
(
0.64%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

p3analyze

Send PM Follow Ignore
Followers 9
Posts 957
Boards Moderated 0
Alias Born 07/16/2006

p3analyze

Re: DewDiligence post# 86332

Monday, 11/16/2009 7:14:08 AM

Monday, November 16, 2009 7:14:08 AM

Post# of 257302
>>With a company as large as BMY, there are always pending clinical developments that could be material to an M&A transaction<<
True, BMY is not a small one-trick pony. Could you educate me on how the suitor will make the M&A economics work if pending clinical development candidates fail to fill the plavix gap in 2012, or was that already built in the stock price? Thanks again!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today